Abstract
Background
Coronavirus disease 2019 (COVID-19), a global issue now, can have a variety of clinical manifestations. Hundreds of articles have discussed different aspects of this infectious disease, such as physiopathology, epidemiology, clinical manifestations and treatment protocols. Recently, neurological manifestations of the disease have been found to be pretty common among COVID-19 patients. Here, neurological symptoms of COVID-19 infection with a focus on non-cerebrovascular complications are discussed in a large study population.
Methods
Neurological symptoms of 891hospitalized COVID-19 patients from March to June 2020 in a major Hospital, Tehran, Iran, were reviewed. Demographic characteristics and neurological manifestations were analyzed.
Results
Among 891 hospitalized COVID-19 patients, the following symptoms were observed: headache (63.9%), sleeping problems (51.3%), hyposmia/anosmia (46%), dizziness (45.4%), hypogeusia (42.1%), memory issues (31.5%), auditory disturbances (17.5%), paralysis (3.7%) and seizures (1.7%). In 29.7% of the patients, a neurological symptom was the initiating symptoms of the infection. Females were more likely to show headache and dizziness compared to males (p value<0.05). Headache intensity was also higher in females compared to males (p value<0.05). Headache prevalence was lower in older patients (p value<0.05), while memory loss and impaired consciousness were higher by increasing age (p values=0.002 and 0.001, respectively).
Conclusion
Neurological manifestations were common among COVID-19 patients under study. Headache, as the most common neurological symptom among COVID-19 patients, was the most prevalent and intense among the female population. Headache, dizziness, sleeping problems, hyposmia/anosmia and hypogeusia were common COVID-19 neurological manifestations, while memory issues, auditory disturbances, paralysis, and seizures were less common.
Keywords: COVID-19, Neurological, Symptom, Headache, Seizures
1. Introduction
Coronavirus disease 2019 (COVID-19) outbreak started from Wuhan, China, in late 2019 [1], presenting with unusual pneumonia of unknown etiology suspiciously related to a seafood market [2]. Today the issue is global with 226,675,069 confirmed cases and 4,663,104 deaths worldwide (until September 15, 2021) [3]. Since the initiation of the pandemic, a huge amount of articles has been published about COVID-19 and a global interest among researchers has been generated, resulting in hundreds of articles discussing the disease’s different aspects, such as epidemiology, clinical presentation, routes of transmission, and therapy protocols [4], [5], [6].
COVID-19 is believed to be transmittable via air droplets during incubation and symptomatic phases. The incubation period of the disease is about five days, on average. The main clinical symptoms of COVID-19 are fever, musculoskeletal pain, dyspnea, dry cough, diarrhea, nausea and vomiting [7], [8], [9], [10], [11], [12]. Most COVID-19 cases (about 80%) experience non-severe disease; however, a few of them (about 20%) develop pneumonia after about five days. Approximately 5% of COVID-19 infected individuals develop severe infection with pulmonary, renal or cardiac failure and ARDS [13], [14]. The disease mortality rate is around 2–3%, while it is believed to be about 4–11% among those who need hospital admission [15].
Although most of the clinical manifestations of COVID-19 are respiratory, cardiac, or gastrointestinal, many patients also experience neurological symptoms. These manifestations can be caused by the direct effect of the virus on the nervous system or para-infectious/post-infectious immune-mediated disorders [16]. The most common neurological symptoms seen during COVID-19 infection are headache, dizziness, olfactory disturbances and neuralgia. On the other hand, some neurological complications, such as cerebrovascular events, impaired consciousness, and encephalopathy are observed as well [17], [18]. Here, 891 COVID-19 cases were studied and neurological manifestations and associations of the disease were discussed in the study population.
2. Material and methods
2.1. Study design and setting
We conducted a retrospective, observational study in a major hospital in capital of Iran, Tehran. We reviewed the medical records of 891 patients diagnosed with COVID-19 referred to the hospital from March 1st to June 30st, 2020. The data was collected by two neurologists using hospital’s health informative system (HIS) via checklists. All patients had a confirmed laboratory diagnosis of COVID-19, either with a positive result for IgG/IgM antibodies against SARS-CoV-2 in a blood test or through detection of SARS-CoV-2 RNA with a real-time reverse transcription-polymerase chain reaction (RT-PCR) of throat swab samples.Demographic data such as age, sex, previous co morbidities (hypertension, diabetes, dyslipidemia, heart disease, immune suppression and neurological diseases) were recorded. We categorized neurological symptoms including headache, dizziness or vertigo, insomnia,impaired consciousness, seizures, paralysis, hearing loss, hyposmia/anosmia and hypogeusia.
All 891 patients included in the study were COVID-19 hospitalized patients of whom 35 ones were admitted to ICU (15 patients due to seizures and 20 patients due to stroke) and 856 patients were admitted to general COVID-19 ward. The severity of COVID-19 disease among patients of this study was ranged from moderate to critical which is defined as; moderate: clinical symptoms such as fever and respiratory manifestations with pneumonia on imaging; severe; at least one criterion of the following: (1) respiratory rate≥30 times/minute with shortness of breath; (2) arterial partial pressure of oxygen/fraction of inspiration of oxygen≤300 mmHg; (3) finger oxygen saturation≤93% in the resting state; and (4) lesion progression of more than 50% in 24–48 h on the chest imaging. Critical: at least one on the following conditions: (1) respiratory failure needing mechanical ventilation; (2) shock; and (3) failure of other organs, and the need for intensive care unit admission [19], [20].
Headache severity was measured using numerical VAS (visual analogue scale) pain scale in which patients are asked to circle the number between 0 and 10 that fits best to their pain intensity [21]. Insomnia was defined as trouble starting or maintaining sleepor Early-morning awakening with inability to return to sleep according to Diagnostic and statistical manual of mental disorders five (DSM5) criteria [22]. Sleep disturbances due to coughing, sneezing and respiratory problems were not considered. Paralysis was defined as hemiplegia, paraplegia and facial paralysis.Memory loss was defined as unusual forgetfulness in which you may not be able to remember new events, recall one or more memories of the past, or both. Stroke was defined as either hemorrhagic or ischemic stroke.
This is a cross sectional and non-interventional study; we did not perform any experiments in human subjects. This study was registered in our center (identifier: 99000321) and it received approval from the institutional ethical standards committee.
2.2. Statistical analysis
The statistical analysis was performed using the SPSS software, version 25 (SPSS, Chicago, IL). The ratios were compared using the Chi squared test and the Fisher’s exact test when the sample size was too small. The comparison between quantitative variables was performed if indicated.Logistic regression analysis was used to evaluate the risk factors for developing neurological symptoms during COVID-19. Variables with P<0.05 in the univariate analysis test were entered into a multivariate logistic regression analysis with the forward method.
3. Results
From a total of 891 COVID-19 patients whom we studied, 3.5% were 10–20 years old, 12% were 21–30, 29.1% were 31–40, 23.1% were 41–50, 20.5% were 51–60, 7.6% were 61–70% and 4.2% were 71 years old or higher. 57.2% of participants were male while 42.8% were female.
55.2% of study participants suffered from underlying disorders with hypertension as the most prevalent disorder (15.4%) and diabetes (11.6%), cardiovascular disease (CVD) (8.5%), respiratory disorders (8.3%) and auto-immune diseases (4.3%) coming next. About 12% of participants mentioned a history of a previously existing neurological disorder with headache and migraine as the most prevalent one (18.7%) and stroke (1.9%) and seizures (1.2%) coming next. ( Table 1).
Table 1.
Underlying neurological and non-neurological conditions.
| Underlying non- neurological conditions | (Prevalence %) | Underlying neurological conditions (prevalence %) | (Prevalence %) |
|---|---|---|---|
| Hypertension | 15.4 | Migraine and other primary headaches | 18.7 |
| Diabetes | 11.6 | ||
| CVD | 8.5 | Stroke | 1.9 |
| Respiratory disorders | 8.3 | Seizures | 1.2 |
| Auto-immune diseases | 4.3 | ||
The findings in two subgroups of patients with and without neurological symptoms during COVID-19 infection revealed that the neurological symptoms have significantly occurred among patients with history of pre-existing neurological conditions [P-value: 0.004,OR: 10.906,CI: (1.498–79.377)] and Migraine and other primary headaches [P-value: 0.007, OR:3.411, CI: (1.351–8.612)], whereas other co-morbidities did not have significant correlation with the distribution of subgroups (with and without neurological symptoms) ( Table 2).
Table 2.
Prevalence of co-morbidities among patients with and without neurological symptoms.
|
Variables |
Neurological symptoms during COVID-19 disease |
Missing patients | P-Value | OR |
95% confidence interval |
|||
|---|---|---|---|---|---|---|---|---|
| Title | Status | Shown [N, (%)] | Not-shown [N, (%)] | Lower | Upper | |||
| Diabetes | Yes | 89,(11.6) | 9,(12.9) | 5 | 0.846 | 0.892 | 0.428 | 1.859 |
| No | 676,(88.4) | 61,(87.1) | 51 | |||||
| Hypertension | Yes | 121,(15.8) | 9,(12.9) | 7 | 0.607 | 1.273 | 0.616 | 2.633 |
| No | 644,(84.2) | 61,(87.1) | 49 | |||||
| Heart diseasea | Yes | 69,(9.0) | 6,(8.6) | 1 | 1.000 | 1.057 | 0.442 | 2.531 |
| No | 696,(91.0) | 64,(91.4) | 55 | |||||
| Respiratory diseaseb | Yes | 68,(8.9) | 4,(5.7) | 2 | 0.394 | 1.610 | 0.569 | 4.552 |
| No | 697,(91.1) | 66,(94.3) | 54 | |||||
| Autoimmune and rheumatologic diseasec | Yes | 35,(4.6) | 3,(4.3) | 0 | 1.000 | 1.071 | 0.321 | 3.574 |
| No | 730,(95.4) | 67,(95.7) | 56 | |||||
| Any pre-existing neurological conditiond | Yes | 104,(13.6) | 1,(1.4) | 3 | 0.004 | 10.906 | 1.498 | 79.377 |
| No | 660,(86.4) | 70,(98.6) | 53 | |||||
| Migraine and other primary headaches | Yes | 159,(20.8) | 5,(7.1) | 3 | 0.007 | 3.411 | 1.351 | 8.612 |
| No | 606,(79.2) | 65,(92.2) | 53 | |||||
| Epilepsy | Yes | 11,(1.4) | 0,(0) | 0 | 0.613 | - | - | |
| No | 754,(98.6) | 70,(100) | 56 | |||||
| Stroke | Yes | 17,(2.2) | 0,(0) | 0 | 0.387 | - | - | |
| No | 748,(97.8) | 70,(100) | 56 | |||||
| Multiple sclerosis | Yes | 6,(0.8) | 0,(0) | 1 | 0.674 | - | - | |
| No | 759,(99.2) | 70,(100) | 55 | |||||
Congestive heart failure (CHF), old myocardial infarction (MI), coronary artery disease (CAD), unstable angina (UA) and arrhythmia.
Asthma, chronic obstructive pulmonary disease(COPD), chronic lung diseases, sinusitis.
Systemic lupus erythematosus, rheumatoid arthritis(RA), behcet’s disease, sjogren’s syndrome.
Any primary chronic headache, stroke, epilepsy, multiple sclerosis (MS), Parkinson’s disease, Alzheimer disease, meningitis, myasthenia gravis and any other confirmed neurological disorder.
An adjusted logistic regression analysis was conducted to evaluate the factors associated with presence of neurological symptoms during COVID-19. Variables with P-value<0.05 in the univariate analysis test including any pre-existing neurological condition and migraine and other primary headaches were entered into logistic regression analysis. Results revealed that these two variables significantly possess predictive values as risk factors for the developing neurological symptoms during COVID-19 [(Any pre-existing neurological condition: ORAdj: 8.315, 95% CI: 1.129–61.235, P-value=0.038),(Migraine and other primary headaches: ORAdj: 2.624, 95% CI:1.030–6.688, P-value=0.043)]( Table 3).
Table 3.
Multivariate logistic regression of variables associated with neurological symptoms during COVID-19.
| variable | P-Value | ORadja |
95% C.Ib |
|
|---|---|---|---|---|
| Lower | Upper | |||
| Any pre-existing neurological condition | 0.038 | 8.315 | 1.129 | 61.235 |
| Migraine and other primary head aches | 0.043 | 2.624 | 1.030 | 6.688 |
Odds ratio adjusted.
95% confidence interval.
Because the CI of any pre-existing neurological disorder was very wide another analysis was done to see whether the significance of any pre-existing neurological disorder was driven by headache or not ( Table 4).
Table 4.
The significance of pre-existing neurological disorders vs. headache.
|
Variables |
Headache during COVID-19 disease |
P-Value | OR |
95% Confidence Interval |
|||
| Title | Status | Yes [N,(%)] | No [N,(%)] | Lower | Upper | ||
| Any pre-existing neurological condition | Yes | 82,(14.4) | 25,(7.8) | 0.005 | 1.977 | 1.235 | 3.166 |
| No | 488,(85.6) | 296,(92.2) | |||||
| Migraine and other primary headaches | Yes | 139,(24.4) | 28,(8.7) | 0.000 | 3.394 | 2.203 | 5.229 |
| No | 430,(75.6) | 294,(91.3) | |||||
| Epilepsy | Yes | 8,(1.4) | 3,(0.9) | 0.755 | 1.516 | 0.399 | 5.756 |
| No | 561,(98.6) | 319,(99.1) | |||||
| Stroke | Yes | 12,(2.1) | 5,(1.6) | 0.621 | 1.366 | 0.477 | 3.912 |
| No | 557,(97.9) | 317,(98.4) | |||||
| Multiple sclerosis | Yes | 6,(1.1) | 1,(0.3) | 0.277 | 3.421 | 0.410 | 28.541 |
| No | 563,(98.9) | 321,(99.7) | |||||
From a total 891 patients of our study, 63.9% mentioned headache, 51.3% mentioned sleeping problems, 46% mentioned hyposmia/anosmia, 45.4% mentioned dizziness, 42.1% mentioned hypogeusia,31.5% mentioned memory issues, 17.5% mentioned auditory disturbances,3.7% mentioned paralysis (hemiplegia, paraplegia and facial paralysis), 1.7% mentioned seizures, and 29.7% mentioned a neurological symptom as the first symptom of the disease during the timeline of COVID-19 infection. Headache was the most prevalent initiator symptom of the disease among those who’s the first illness symptom was a neurological one (26.6%) ( Table 5).
Table 5.
Prevalence of neurological symptoms in COVID-19 patients.
| Neurological symptom | Prevalence (%) | Neurological symptom | Prevalence (%) |
|---|---|---|---|
| Headache | 63.9 | Memory issues | 31.5 |
| Sleeping problems | 51.3 | Auditory disturbances | 17.5 |
| Hyposmia/anosmia | 46 | Paralysis | 3.7 |
| Dizziness | 45.4 | Seizures | 1.7 |
| Hypogeusia | 42.1 | ||
Headache and dizziness were significantly higher among female COVID-19 patients rather than male ones (p value<0.05). Other neurological symptoms did not show significant difference by sex. Age was found to be effective on prevalence of headache, memory loss and impaired consciousness. We found that headache prevalence decreases in older patients (p value<0.05). Headache as a neurological presentation of COVID-19 was mostly seen among patients between 31 and 40 years of age. On the other hand, the prevalence of memory loss and impaired consciousness are increased in older participants (p values=0.002 and 0.001 respectively) ( Table 6).
Table 6.
Distribution of symptoms by age.
| Age | 10–20 N, (%) | 21–30 N, (%) | 31–40 N, (%) | 41–50 N, (%) | 51–60 N, (%) | 61–70 N, (%) | >70 N, (%) | P value |
|---|---|---|---|---|---|---|---|---|
| Symptom prevalence | ||||||||
| Headache | 21,(67.7) | 73,(68.2) | 182,(70.3) | 141,(68.4) | 103,(56.3) | 31,(45.6) | 18,(48.6) | 0.000 |
| Memory loss | 8,(26.7) | 16,(16.3) | 81,(32.5) | 64,(33) | 53,(30.5) | 25,(39.7) | 19,(52.8) | 0.002 |
| Impaired consciousness | 3,(10) | 2,(2) | 11,(4.4) | 10,(5.2) | 14,(8.2) | 8,(13.1) | 9,(25) | 0.001 |
| Dizziness | 14,(48.3) | 38,(38) | 121,(48.2) | 98,(51.3) | 70,(41.4) | 22,(35.5) | 18,(48.6) | 0.634 |
| Hyposmia/anosmia | 12,(38.7) | 47,(49) | 116,(46.8) | 101,(52.3) | 65,(38.7) | 27,(42.9) | 16,(44.4) | 0.299 |
| Dysgeusia | 11,(39.3) | 39,(40.2) | 104,(41.8) | 94,(49.2) | 65,(38.7) | 22,(37.3) | 13,(37.1) | 0.715 |
| Auditory disturbances | 2,(6.7) | 14,(14.4) | 44,(17.1) | 37,(19.1) | 31,(18.5) | 10,(16.4) | 8,(22.9) | 0.191 |
| Sleeping problems | 13,(43.3) | 45,(46.4) | 124,(49.6) | 111,(56.9) | 81,(47.4) | 32,(53.3) | 24,(66.7) | 0.146 |
| Seizures | 1,(3.3) | 0,(0) | 2,(0.8) | 5,(2.6) | 4,(2.3) | 1,(1.6) | 1,(2.9) | 0.152 |
| Paralysis | 1,(3.2) | 3,(2.8) | 8,(3.1) | 2,(1) | 12,(6.6) | 3,(4.4) | 4,(10.8) | 0.063 |
The most common neurological symptom among both female and male subgroups was headache. The pattern of headache and dizziness is discussed in Table 7. Headache was significantly more intense among females rather than males (p value<0.05) while the intensity of other neurological symptoms did not show statistically significant difference between male and female subgroups.
Table 7.
Headache pattern of COVID-19 patients.
| Headache pattern | Prevalence (%) | Dizziness pattern | Prevalence (%) |
|---|---|---|---|
| Global | 31.2 | Feeling of imbalance | 26 |
| One-sided | 18.2 | Light headedness | 16 |
| Tensional | 15.3 | True vertigo | 9.3 |
| Pulsate | 12.6 | ||
| Accompanied by nausea and vomiting | 10.5 | ||
| Sharp stabbing | 2.5 | ||
Previously existing diseases were effective in prevalence of neurological symptoms among COVID-19 patients as we found that headache, dizziness, hyposmia/anosmia, hypogeusia, auditory disturbances, sleeping problems, memory loss and paresthesis in hands and feet were significantly higher among patients with underlying disorders in compare to others (p values=0.001, 0.007, 0.014, 0.011, 0.005, 0.035, 0.001 and 0.011 respectively).
Underlying neurological diseases were found to be effective in prevalence of neurological symptoms among COVID-19 cases. We determined that headache,hyposmia/anosmia, hypogeusia, sleeping problems, paresthesis in hands and feet, paralysis, impaired consciousness and memory loss are significantly higher among patients with Underlying neurological diseases comparing to others (p values=0.005, 0.048, 0.027, 0.001, 0.024, 0.020, 0.003 and 0.018 respectively). The most prevalent neurological underlying disorder among COVID-19 patients who experienced neurological symptoms was headache which was seen in almost 75% of participants with neurological symptoms as a neurological underlying disorder. On the other hand, the most prevalent preexisting non-neurological disorder among COVID-19 patients was hypertension which was seen in 12.5% of COVID-19 cases with neurological symptoms.
Stroke as an important neurological underlying condition was seen mostly among patients over 70 years old while seizures was an underlying condition seen mostly among patients between 10 and 20 years of age.
4. Discussion
In this retrospective observational study, neurological manifestations were shown to be pretty common among COVID-19 patients. In several cases (27%), the initiating symptoms of the illness were neurological. 63.9% of the study population presented at least one neurological symptom during the course of infection, which was pretty higher than the proportion suggested by previous data [23].
The mechanism of neurologic involvement during COVID-19 infection is believed to be either a direct effect of the virus on the nervous system or an indirect neurological effect caused by Para-infectious/post-infectious immune-mediated disease that leads to a breakdown in the blood-brain barrier (BBB), leaving it permeable to cytokines and making the nervous system vulnerable to neuro-inflammatory reactions [12], [23], [24], [25], [26], [27]. Direct COVID-19 neurologic invasion has been rarely described in the previous data. Moriguchi et al. reported a 24 years old man in Japan presenting with generalized seizures and reduced consciousness, whose CSF analysis was positive for COVID-19, and then the patient was diagnosed with SARS-COV-2 encephalitis [25]. Sohal et al. reported a 72 years old man in the USA presented with light headedness, altered mental status and seizures; he had a positive RT-PCR sample (source not specified) and then diagnosed with COVID-19 encephalitis [28]. Wong et al. reported a 40 years old man in the UK who presented with diplopia, ataxia, oscillopsia, and bilateral facial weakness (rhombencephalitis), whose nasopharyngeal swab sample was positive for COVID-19; however, CSF analysis was not performed and finally, he was diagnosed with COVID-19 encephalitis [29]. Another interesting study was a case report by Paniz-Mondolfi et al. about a patient presented with confusion, who finally died; the post-mortem analysis of this case showed the presence of the COVID-19 virus in the patient’s frontal lobe neurons and brain endothelial cells [26]. Among 891 patients of the current study, we had two unique cases which were previously published as case reports; A 40 y/o male with diplopia, nystagmus, and gait disorders who was diagnosed with CNS vasculopathy(arteritis) and discharged with full recovery after treatment and an 18 y/o female with generalized tonic-clonic seizures and a three week history of mood changes and depression accompanied by lack of concentration who was diagnosed with simultaneous anti-NMDAR and COVID-19 encephalitis and discharged with full recovery after treatment [30], [31].
Underlying disorders in the current study were very much similar to the previous research. Hypertension was found as the most common underlying disorder among the study population (15.4%), similar to many earlier studies [32], [33], [34], [35], [36]. The next underlying disorders by prevalence order were: diabetes (11.6%), cardiac conditions (8.5%), respiratory disease (8.3%) and autoimmune disorders (4.3%). Pre-existing neurological conditions were also analyzed in the present study; it was shown that about 12% of the study population had a history of neurological diseases with headache and migraine as the most prevalent (18.7%), followed by stroke (1.9%) and epilepsy (1.2%). Previous data from Spain shows lower portions of pre-existing neurological disorders (8.4%) compared to the present study [23]. The novelty of the current work was to analyze the possible correlation between underlying neurological and non-neurological disorders and the risk of developing neurological symptoms. It was found that pre-existing neurological condition and migraine and other primary headaches were risk factors to develop neurological symptoms during the course of COVID-19 infection.
Headache has been discussed as one of the most prevalent non-specific neurological symptoms of COVID-19 in prior studies [23], [24], [37], [38], [39], [40], [41]. Another novelty of this experience was to analyze the pattern of headache as the most prevalent neurological symptom among the study population. Further, the prevalence of COVID-19-related headaches was analyzed in different age periods, and it was found that the peak of headache prevalence occurred in patients between 31 and 40 years old; however, it declined above this age. Memory loss and impaired consciousness, on the other hand, were positively correlated with age.
The peripheral nervous system (PNS) can be invaded by COVID-19, just like the central nervous system (CNS). Cranial and peripheral nerves can be involved during COVID-19 infection with direct and indirect mechanisms, as discussed before. Viral entry points to the PNS remain unclear; however, recently, it has been discovered that goblet and ciliated cells can be potential entry points for the SARS-COV-2 virus to PNS [29]. Both goblet and ciliated cells over express ACE2 receptors, which are COVID-19′s main entry routes to the cells [36]. Cranial nerve involvement can lead to hyposmia/anosmia, dysgeusia, and auditory disturbances, all of which are observed in the current experience. Peripheral nerve involvement can result in peripheral paralysis, which is also discussed in the present study.
Hyposmia/anosmia and hypogeusia are common neurological manifestations in the present study with higher occurrences compared to the Spanish population [23]. The exact underlying mechanism of hyposmia/anosmia and hypogeusia in COVID-19 infection remains unclear; however, theoretically, it can be a result of damage to the nasal epithelium or direct damage to the olfactory nerve and olfactory bulb [42], [43]. These two symptoms are believed to be indicators of early infection [17], [42], [44]. However, these symptoms are not analyzed in the present work by the exact time of their occurrence in the infection timeline. This study shows that a small proportion of patients(3.7%) experience paralysis in different forms: 1.1% experience hemiplegia mostly seen in cerebrovascular events, 1.6% experience paraplegia possibly due to cerebrovascular events or peripheral neuropathy and 1.6% experience one-sided facial paralysis observed in both CNS and PNS involvement.
Dizziness is also a frequently mentioned symptom in earlier research [23], [24], [37], [38], [39], [40], [41]; however, the exact pattern of dizziness was analyzed in the current research. In this experience, sex is found to be effective in the prevalence of neurological symptoms of COVID-19. Further, it is showed that female patients are more likely to develop headaches and dizziness compared to male ones, while other neurological symptoms are not influenced by sex.
This study was designed to evaluate neurological symptoms of COVID-19. Outcomes of the disease were not to be evaluated in this study. However, it is recommended to evaluate outcomes of patients with COVID-19 related neurological symptoms in the further studies.
5. Conclusion
In conclusion, neurological manifestations were pretty common among COVID-19 patients. These manifestations can be initiated before the COVID-19 symptoms or appear later in the course of infection. Headache was the most common neurological symptom among COVID-19 patients with higher prevalence and intensity among the females. Headache, dizziness, sleeping problems, hyposmia/anosmia and hypogeusia were very common neurological manifestations of COVID-19 infection, while memory issues, auditory disturbances, paralysis and seizures were other less common ones. Further investigation in larger scales is recommended to get more precise results about COVID-19 neurological manifestations.
Funding
None.
Acknowledgements
Thanks to guidance and advice from Clinical Research Development Unit of Baqiyatallah Hospital, Tehran, Iran.
Data Availability Statement
Any data used to write this article is available and will be shared if necessary. All Statistical analysis files and data are available and will be shared in necessary.
References
- 1.Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G.F., Tan W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Halaji M., Farahani A., Ranjbar R., Heiat M., Dehkordi F.S. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Infez. Med. 2020;28(Suppl 1):6–17. [PubMed] [Google Scholar]
- 3.Worldometers. Confirmed Cases and Deaths by Country, Territory, or Conveyance. 〈https://www.worldometers.info/coronavirus/〉. 2020.
- 4.Mirzaei R., Karampoor S., Sholeh M., Moradi P., Ranjbar R., Ghasemi F. A contemporary review on pathogenesis and immunity of COVID-19 infection. Mol. Biol. Rep. 2020;47(7):5365–5376. doi: 10.1007/s11033-020-05621-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Mohammadpour S., TorshiziEsfahani A., Halaji M., Lak M., Ranjbar R. An updated review of the association of host genetic factors with susceptibility and resistance to COVID-19. J. Cell Physiol. 2021;236(1):49–54. doi: 10.1002/jcp.29868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sheikhshahrokh A., Ranjbar R., Saeidi E., SafarpoorDehkordi F., Heiat M., Ghasemi-Dehkordi P., Goodarzi H. Frontier therapeutics and vaccine strategies for SARS-CoV-2 (COVID-19): a review. Iran J. Public Health. 2020;49(Suppl 1):18–29. doi: 10.18502/ijph.v49iS1.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhao S., Musa S.S., Lin Q., Ran J., Yang G., Wang W., Lou Y., Yang L., Gao D., He D., Wang M.H. Estimating the unreported number of novel coronavirus (2019-nCoV) cases in China in the first half of January 2020: a data-driven modelling analysis of the early outbreak. J. Clin. Med. 2020;9(2):388. doi: 10.3390/jcm9020388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London England) 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Rothe C., Schunk M., Sothmann P., Bretzel G., Froeschl G., Wallrauch C., Zimmer T., Thiel V., Janke C., Guggemos W., Seilmaier M., Drosten C., Vollmar P., Zwirglmaier K., Zange S., Wölfel R., Hoelscher M. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N. Engl. J. Med. 2020;382(10):970–971. doi: 10.1056/NEJMc2001468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ryu S., Chun B.C., KS of Epidemiology An interim review of the epidemiological characteristics of 2019 novel coronavirus. Epidemiol. Health. 2020:42. doi: 10.4178/epih.e2020006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Jernigan DB. Update: Public Health Response to the Coronavirus Disease 2019 Outbreak‚ ÄîUnited States, February 24, 2020. MMWR Morbidity and mortality weekly report. 2020; 69. [DOI] [PMC free article] [PubMed]
- 14.Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., Diaz G., Cohn A., Fox L., Patel A., Gerber S.I., Kim L., Tong S., Lu X., Lindstrom S., Pallansch M.A., Weldon W.C., Biggs H.M., Uyeki T.M., Pillai S.K. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 2020;382:929–936. doi: 10.1056/NEJMoa2001191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Nishiura H., Kobayashi T., Yang Y., Hayashi K., Miyama T., Kinoshita R., et al., The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights. Multidisciplinary Digital Publishing Institute, 2020. [DOI] [PMC free article] [PubMed]
- 16.Ellul M.A., Benjamin L., Singh B., Lant S., Michael B.D., Easton A., Kneen R., Defres S., Sejvar J., Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–783. doi: 10.1016/S1474-4422(20)30221-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., Miao X., Li Y., Hu B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi: 10.1001/jamaneurol.2020.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., Collange O., Boulay C., Fafi-Kremer S., Ohana M., Anheim M., Meziani F. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 2020;382:2268–2270. doi: 10.1056/NEJMc2008597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 2020;94(7):e00127–20. doi: 10.1128/JVI.00127-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zu Z.Y., Jiang M.D., Xu P.P., Chen W., Ni Q.Q., Lu G.M., Zhang L.J. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology. 2020;296(2):E15–E25. doi: 10.1148/radiol.2020200490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hawker G.A., Mian S., Kendzerska T., French M. Measures of adult pain: Visual analog scale for pain (vas pain), numeric rating scale for pain (nrs pain), mcgill pain questionnaire (mpq), short‚Äêform mcgill pain questionnaire (sf‚Äêmpq), chronic pain grade scale (cpgs), short form‚Äê36 bodily pain scale (sf‚Äê36 bps), and measure of intermittent and constant osteoarthritis pain (icoap) Arthritis Care Res. 2011;63(S11):S240–S252. doi: 10.1002/acr.20543. [DOI] [PubMed] [Google Scholar]
- 22.American Psychiatric A, Diagnostic and Statistical Manual of Mental Disorders (DSM-5¬Ž): American Psychiatric Pub, 2013.
- 23.Romero-S√°nchez C.M., D√‡az-Maroto I., Fern√°ndez-D√‡az E., S√°nchez-Larsen Å., Layos-Romero A., Garc√‡a-Garc√‡a J., et al. Neurological manifestations in hospitalized patients with covid-19: a retrospective, observational study from a spanish population. ALBACOVID Regist. 2020 [Google Scholar]
- 24.Ellul M., Benjamin L., Singh B., Lant S., Michael B., Kneen R. et al., Neurological Associations of COVID-19. Available at SSRN 3589350. 2020. [DOI] [PMC free article] [PubMed]
- 25.Moriguchi T., Harii N., Goto J., Harada D., Sugawara H., Takamino J., Nakao A. A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Int. J. Infect. Dis. 2020;94:55–58. doi: 10.1016/j.ijid.2020.03.062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Paniz‐Mondolfi A., Bryce C., Grimes Z., Gordon R.E., Reidy J., Lednicky J., Sordillo E.M., Fowkes M. Central nervous system involvement by severe acute respiratory syndrome coronavirus‚Äê2 (SARS‚ÄêCoV‚Äê2) J. Med. Virol. 2020;92(7):699–702. doi: 10.1002/jmv.25915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Platt M.P., Bolding K.A., Wayne C.R., Chaudhry S., Cutforth T., Franks K.M., Agalliu D. Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis. Proc. Natl. Acad. Sci. 2020;117(12):6708–6716. doi: 10.1073/pnas.1911097117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Sohal S., Mossammat M. COVID-19 presenting with seizures. IDCases. 2020;20 doi: 10.1016/j.idcr.2020.e00782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wong P.F., Craik S., Newman P., Makan A., Srinivasan K., Crawford E., Dev D., Moudgil H., Ahmad N. Lessons of the month 1: a case of rhombencephalitis as a rare complication of acute COVID-19 infection. Clin. Med. 2020;20(3):293–294. doi: 10.7861/clinmed.2020-0182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Allahyari F., Hosseinzadeh R., Nejad J.H., Heiat M., Ranjbar R. A case report of simultaneous autoimmune and COVID-19 encephalitis. J. Neurovirol. 2021:1–3. doi: 10.1007/s13365-021-00978-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Hosseini M.J., Halaji M., Nejad J.H., Ranjbar R. Central nervous system vasculopathy associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a novel case report from Iran. J. Neurovirol. 2021:1–3. doi: 10.1007/s13365-021-00979-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Xiang T.X., Liu J.M., Xu F., Cheng N., Liu Y., Qian K.J. Analysis of clinical characteristics of 49 patients with novel coronavirus pneumonia in Jiangxi province. Chin. J. Respir. Crit. Care Med. 2020;19(2):1–7. [Google Scholar]
- 33.Wang Z., Yang B., Li Q., Wen L., Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin. Infect. Dis. 2020;71:769–777. doi: 10.1093/cid/ciaa272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.C. Qin, MDPLZMD Ziwei, SYMDY Tao, PCXMDP Ke, MMDPK Shang, Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China, Clinical Infectious Diseases, Oxford Academic, Clinical Infectious Diseases.
- 35.Liu W., Tao Z.-W., Wang L., Yuan M.-L., Liu K., Zhou L., Wei S., Deng Y., Liu J., Liu H.G., Yang M., Hu Y. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin. Med. J. 2020;133:1032–1038. doi: 10.1097/CM9.0000000000000775. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Chen C., Yan J.T., Zhou N., Zhao J.P., Wang D.W. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua xin xue guan Bing. za zhi. 2020;48:567–571. doi: 10.3760/cma.j.cn112148-20200225-00123. E008-E008. [DOI] [PubMed] [Google Scholar]
- 37.Ahmed M.U., Hanif M., Ali M.J., Haider M.A., Kherani D., Memon G.M., Karim A.H., Sattar A. Neurological manifestations of COVID-19 (SARS-CoV-2): a review. Front. Neurol. 2020;11:518. doi: 10.3389/fneur.2020.00518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Tsivgoulis G., Palaiodimou L., Katsanos A.H., Caso V., Köhrmann M., Molina C., et al. <? covid19?> Neurological manifestations and implications of COVID-19 pandemic. Ther. Adv. Neurol. Disord. 2020;13 doi: 10.1177/1756286420932036. 1756286420932036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Fiani B., Covarrubias C., Desai A., Sekhon M., Jarrah R. A contemporary review of neurological sequelae of COVID-19. Front. Neurol. 2020;11:640. doi: 10.3389/fneur.2020.00640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Gklinos P. Neurological manifestations of COVID-19: a review of what we know so far. J. Neurol. 2020;267:1–2489. doi: 10.1007/s00415-020-09939-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Nejad J.H., Heiat M., Hosseini M.J., Allahyari F., Lashkari A., Torabi R., et al. Guillain-Barré syndrome associated with COVID-19: a case report study. J. Neurovirol. 2021:1–4. doi: 10.1007/s13365-021-00984-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Beltrán‐Corbellini Á., Chico‐García J.L., Martínez‐Poles J., Rodríguez‐Jorge F., Natera‐Villalba E., Gómez‐Corral J., Gómez‐López A., Monreal E., Parra‐Díaz P., Cortés‐Cuevas J.L., Galán J.C., Fragola‐Arnau C., Porta‐Etessam J., Masjuan J., Alonso‐Cánovas A., Beltrán‐Corbellini Á., Chico‐García J.L., Martínez‐Poles J., Rodríguez‐Jorge F., Alonso‐Cánovas A. Acute‚ Äêonset smell and taste disorders in the context of COVID‚Äê19: a pilot multicentre polymerase chain reaction based case‚ Äìcontrol study. Eur. J. Neurol. 2020;27:1738–1741. doi: 10.1111/ene.14273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Baig A.M. Neurological manifestations in COVID‚Äê19 caused by SARS‚ ÄêCoV‚ Äê2. CNS Neurosci. Ther. 2020;26(5):499–501. doi: 10.1111/cns.13372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Lechien J.R., Chiesa-Estomba C.M., Place S., Van Laethem Y., Cabaraux P., Mat Q., Huet K., Plzak J., Horoi M., Hans S., Rosaria Barillari M., Cammaroto G., Fakhry N., Martiny D., Ayad T., Jouffe L., Hopkins C., Saussez S., COVID- Task Force of Y. Clinical and epidemiological characteristics of 1420 European patients with mild‚ Äêto‚ Äêmoderate coronavirus disease 2019. J. Intern. Med. 2020;288(3):335–344. doi: 10.1111/joim.13089. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Any data used to write this article is available and will be shared if necessary. All Statistical analysis files and data are available and will be shared in necessary.